Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
A number of studies have shown that certain blood-pressure medications such as ACE-inhibitors
and angiotensin-II-receptor blockers (ARB) can reduce the incidence of diabetes mellitus type
2. This protocol will evaluate whether inflammatory mechanisms mediate this effect. The
investigators therefore will investigate the effect of telmisartan, a potent ARB, on lipid
metabolism, glucose metabolism and inflammation in patients with the metabolic syndrome.
Specific parameters will be tested before treatment and after 3 months of treatment. Placebo
will be compared to 2 different doses of telmisartan per day.